ASSESSMENT OF THE COMBINATION OF FENOFIBRATE AND SILDENAFIL IN ALZHEIMER’S DISEASE

The purpose of the study was to evaluate the effectiveness of fenofibrate and sildenafil at various dosages in the treatment of Alzheimer’s disease. Sildenafil is an up-regulator of brain-derived neurotrophic factor (BDNF), whereas fenofibrate is a powerful PPAR-α activator. The typical medication was rivastigmine, while the inducer was AlCl3 . The tests of spatial working memory included the MWM, Y-Maze, and NOR. Moreover, the levels of Aβ, PPAR-α, BDNF, TNF-α, and IL-1β in the brain were measured using ELISA kits. During the probing session, the MWM displayed a decline in escape latency and rise in the target quadrant entry. The results of the Y-maze and the NOR demonstrated the emergence of spontaneous changes in the discrimination and recognition index scores. The therapy groups showed decline in the levels of TNF-α, IL-1β, and Aβ. The brain histology of the treated group showed moderate neurodegeneration. From this study, we can conclude that fenofibrate and sildenafil when used in combination could be a successful treatment for AD.